CXCR2 and breast carcinoma: CXCR2 antagonism was tested in combination with immunotherapy consisting of adenovirus encoded TNF-related apoptosis ligand (TRAIL) plus TLR9 agonist, CpG, oligonucleotide (AdT + CpG) in a murine model of breast cancer.